Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

http://www.silence-therapeutics.com).  Copies of the Circular will be also available from the offices of Silence plc, The Royal Institution of Great Britain, 21 Albermarle Street, London, W1S 4BS and at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH.

Jerry Randall, Chairman, said: "In very challenging markets, Silence Therapeutics has secured commitments from existing and new shareholders to raise at least £5.2 million. Over the next two years we expect to conclude multiple value-driving events including completion of a second clinical trial of Atu027. The proceeds from this fundraising will strengthen the balance sheet with a view to ensuring that Silence extracts the highest value from its products and RNAi technology platform."

Background to and Reasons for the Fundraising and Use of Proceeds

On 21 March 2012, the Company announced its unaudited preliminary results for the 12 months ended 31 December 2011. In this announcement, the Company disclosed that the Group had cash resources which, based on the current levels of cash expenditure, are expected to last into the second half of 2012. As a consequence, the Group stated that it would require additional finance at some point in the future to enable its strategy for creating Shareholder value to be implemented in an optimal manner.

It is the intention of the Directors that the amount of £5.2 million (before costs) being raised from the Subscription and the Convertible Loan Note will be used to support the development of the RNAi platform as outlined below.

The proceeds of the Fundraising will enhance the Group's financial position and provide it with sufficient cash resources to fund the business until 2014. This injection of funding would extend the existing window of opportunity for exploitation of the RNAi platform and the Company's lead development candidate Atu027. In particular, it would enable the Company t
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015  23andMe, the leading personal genetics company, ... as Privacy Officer and Corporate Counsel. Black brings a ... as well as health care regulations. As a member ... responsible for reviewing, updating and enhancing the company,s privacy ... abroad. She joined the company January 5, 2015 and ...
(Date:2/26/2015)... Protiviti ( www.protiviti.com ), a global consulting ... Governance Portal , designed to increase the efficiency with ... across multiple business units and projects. The Governance Portal ... align their controls with the COSO ( Committee of ... response to client feedback, Protiviti has also included a ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015  NuGene ... age-defying aesthetic products for skin and hair rejuvenation, ... Relations as agency of record for investor relations ... to improve our distribution, sales and diversification strategies ... to current and prospective shareholders," stated Ali Kharazmi ...
(Date:2/26/2015)... February 26, 2015 Already well respected ... line by expanding its Length Gauge offerings with new ... , Specifically, HEIDENHAIN’s pencil probe-style SPECTO length ... specification. Two new 1Vpp, 12mm stroke length variants ... applications. One is a variant with a weak spring, ...
Breaking Biology Technology:23andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2
... Zyvex Labs today announced,its first company spinout: ... Rob,Burgess, PhD, former Vice President of Research & ... Group Leader of Life Sciences,at Zyvex Corporation. ... in Life,Sciences. The company seeks to apply nanoparticle ...
... The law firm of Finkelstein,Thompson LLP announces that ... States District Court for the Southern District of New ... stock of GPC Biotech AG,("GPC Biotech" or the "Company") ... 24, 2007, inclusive (the "Class Period"). Finkelstein Thompson LLP,is ...
... MINNEAPOLIS, Aug. 21 Vital Images, ... of enterprise-wide advanced,visualization and analysis solutions, today ... advanced visualization and analysis product,solutions with the ... This,comprehensive package offers powerful advanced visualization and ...
Cached Biology Technology:NanoMed, Inc. Spins Out of Zyvex Labs 2Finkelstein Thompson LLP Announces GPC Biotech AG Investigation 2Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 2Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 3Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1 4
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... on the way for millions of people on the East ... have reported a key advance in efforts to develop the ... major nuisance to homeowners and a devastating pest to some ... that infects a common weed and found that it shows ...
... at the 35th Congress of the European Society for Medical ... Italy, presented results that suggested it may be possible to ... to respond to subsequent lines of chemotherapy. Dr Bernardo,s ... metastatic breast cancer in their centre between 1992 and 2006. ...
... drug being developed as a treatment for ovarian cancer has ... patients in a Phase-II clinical trial, an international research group ... Institute in the USA reported the results of the single-agent ... the 35th Congress of the European Society for Medical Oncology ...
Cached Biology News:Progress toward first commercial repellent for East Coast's stinker 2Investigational ovarian cancer drug shows promise against platinum resistant disease 2
... cells were cultured in Ham's F12K medium with ... phase of growth. In order to keep the ... in acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
... Plus Microsphere/Microarray Stabilizer is an aqueous solution ... other non-toxic chemicals in a PBS buffer ... This product contains a combination of ... preservative. StabilCoat Plus Stabilizer provides optimum ...
... The mini incubation trays ... used to screen antigens that ... membrane. Each tray has eight ... channels that accommodate strips cut ...
Biology Products: